Developing a new therapeutic is risky, notoriously slow, and can cost billions of dollars. 90% of drug candidates fail beyond phase 1 trials. Today, we're excited to release TxGemma, a collection of open models designed to improve the efficiency of therapeutic development by leveraging the power of large language models.Building on Google DeepMind's Gemma, a family of lightweight, state-of-the-art open models, TxGemma is specifically trained to understand and predict the properties of therapeuti...